Samsung Biologics achieved record annual revenue of 4.55 trillion won in 2024, with a 23 percent increase year over year.
Samsung Biologics is set to secure multiple deals for its new antibody-drug conjugate business at the J.P. Morgan Healthcare Conference.
Samsung Biologics plans to build a sixth manufacturing plant in Incheon by 2027 while exploring M&A opportunities.
Samsung Biologics has secured a record $1.41 billion contract with an unnamed European pharmaceutical company, the contract development and manufacturing organization (CDMO) announced in an electronic disclosure Tuesday.
Samsung Biologics and Ligachem Biosciences will expand their collaboration on projects to develop antibody-drug conjucates used in cancer treatments.
Korean biopharmaceutical firms Samsung Biologics, Celltrion, and Lotte Biologics will showcase their advancements at the J.P. Morgan Healthcare Conference.
Samsung Biologics has signed a contract worth 111.2 billion won with an undisclosed U.S. pharmaceutical firm to provide contract manufacturing organization services.
Samsung Biologics has established a corporate social responsibility program that applies 5 to 15 percent of its employees' spending at certain stores to a charity fund for children in need in Incheon.
Samsung Biologics has secured two deals valued at 930.4 billion won ($668.4 million) with an unnamed European pharmaceutical company, the biotech firm said Wednesday.
Samsung Biologics said on Friday that it was granted three certifications from the International Organization for Standardization (ISO), including for compliance management and information security.
Korea JoongAng Daily Sitemap
